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1. Introduction 
Clinical research studies in general aim to help answer questions that patients most 
frequently ask their physicians (or these ask themselves): What is wrong with me 
(diagnosis)? What can you do for me (treatment)? Will I get better (prognosis)?  
Diagnosis, prognosis and treatment are obviously related, although not so simply as might 
be thought at first sight, with prognosis and treatment being dependent on a previously 
established diagnosis. In fact, the information produced in any of these three activities of 
clinical practice influences the others and they are much interdependent. For example, 
prognostic information provides the final confirmation of the diagnosis in some cases, and 
response to treatment can be used as evidence in favor of a suspected diagnosis. Also, a 
diagnosis is often immediately connoted with a certain prognosis and the need for certain 
treatments, and these may be more important to the patient than the diagnosis itself. A good 
example of this is cancer, with its expected ominous outcomes and fearful treatments. 
Another type of concern raised in clinical practice, but of more general interest, is usually 
addressed in more wide scope epidemiological studies (What caused my illness (etiology)?) 
and will not be approached in this chapter. 
The purpose of this chapter is to review the essentials of clinical epidemiology as a bridging 
discipline that provides information useful to care for individual patients. The approach to 
the theme is based on an overview of the modern probabilistic approach to diagnosis, 
prognosis and assessment of disease management in heart failure. 
Heart failure is a complex syndrome with a large and increasing burden that poses 
interesting and at times unresolved challenges in all the issues that are to be technically 
discussed. We aim at providing the concepts and guiding the development of competencies 
necessary for using the medical literature and making clinical decisions. 
2. Diagnosis 
As Edmond A. Murphy put in his claim for the need for a theory of Medicine, “There is 
probably no more important field in Medicine than diagnosis and none more difficult to 
teach. It seems astonishing that it is not attracting hundreds of theorists. We have a crisis of 
medical care on our hands, and the need to optimize the efficiency of diagnosis is obvious. 
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What work has been done on diagnosis and by whom? Some statisticians have developed 
algebraic models; but since they have never seen the diagnostician at work, the models are 
hopelessly unrealistic. Some few clinicians have accepted the idea that diagnosis is a 
straightforward application of Bayes’ theorem. (…) These imported approaches will not do 
because they do not start from, and attempt to refine, how the process works in clinical 
practice. The diagnostic process is a sequential strategy in which the facts are 
nonindependently and nonidentically distributed, usually collected not singly but in 
groups, and with an end point constrained by urgency, compassion, cost and redundancy. 
No useful solution to that challenge is likely to be successful unless the first goal is to specify 
what the clinician is trying to do” (Murphy, 1997). 
The clinical diagnosis of heart failure is unreliable and current recommendations for 
diagnosis warrant the objective demonstration of cardiac structural or functional 
abnormalities, usually by echocardiogram (Dickstein et al., 2008). However, its syndromic 
nature implies that symptoms and signs are the fundamental basis of diagnosis and 
echocardiographic measurements are also susceptible to measurement error and are 
strongly observer-dependent. To complicate things further, objective evidence of diastolic 
dysfunction of some form is currently recommended for the diagnosis of heart failure with 
preserved ejection fraction (Paulus et al., 2007), which used to be an exclusion diagnosis. 
This contrasts with the past reliance mainly on left ventricular systolic dysfunction as the 
underlying cardiac functional abnormality to explain a clinical picture of heart failure, with 
the exception of valvular heart disease. Diastolic function is technically more difficult to 
characterize by echocardiogram. Symptoms and signs of heart failure and objective evidence 
of cardiac dysfunction must both be present for a diagnosis of heart failure to be established, 
and in case of doubt response to treatment can be considered (Dickstein et al., 2008). 
There is no consensual gold standard for the diagnosis of heart failure and the current best 
reference is an expert’s opinion based on clinical, laboratorial and functional data.  
Plasma concentrations of natriuretic peptides are useful biomarkers in the diagnosis of heart 
failure. B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) rise in 
response to an increase in myocardial wall stress. Evidence exists supporting their use for 
diagnosing, staging, making hospitalization/discharge decisions, and identifying patients at 
risk for clinical events. The evidence for their use in monitoring and adjusting drug therapy 
is less clearly established. There is no definitive cut-off value recognized for either of the two 
natriuretic peptides for the diagnosis of HF. A normal concentration in an untreated patient 
has a high negative predictive value and makes HF an unlikely cause of symptoms 
(Bettencourt, 2005; Dickstein et al., 2008). 
2.1 Concordance 
Diagnosis starts with clinical history collection and registration. 
To assess the relative completeness and validity of data sources for evaluating the quality of 
care, 1270 patients with at least one of a set of chronic diseases were sampled from 39 
American medical organizations and surveyed. Self-reported information and ambulatory 
care record data were compared to assess concordance (Tisnado et al., 2006). 
In this study, the prevalence of previous diagnosis of heart failure was 13% according to the 
medical record, 9% according to patient’s self-report and 18% according to one or both 
www.intechopen.com
 
Clinical Epidemiology: Principles Revisited in an Approach to Study Heart Failure 
 
173 
sources. The proportion of cases in which medical records and patient’s self-report agreed 
regarding previous history of heart failure was 86%, which might seem high. However, if 
the data in medical records and patient’s self-report were truly independent, that is if 
having a diagnosis of heart failure registered in the medical record was in no way related 
with the probability of the patient reporting such diagnosis (the extreme, and for this matter 
absurd, situation of independence, the null hypothesis), then by chance alone agreement 
could be observed in some cases. This effect of chance is usually the most difficult to 
understand, but the point is in the concept of statistical independence. 
Consider the raw data presented in the following table: 
 Medical record  
 Heart failure No heart failure Total 
Patient’s  
self-report 
Heart failure 50 a 64 b 114 
No heart failure 115 c 1041 d 1156 
 Total 165 g 1105 g 1270 
Table 1. Cross-classification of diagnosis of heart failure according to data source. In 
concordance tables, paired data are presented so the number of observations is the number 
of subjects but for each subject two variables are being presented at the same time; for 
instance, in the first cell 50 cases are counted with heart failure registered in the medical 
record and also reported by the patient. (Note: the data presented in this table were derived 
for the purpose of presentation but were not published as such in the original paper 
(Tisnado et al., 2006) and it is possible they are not real.) 
Under independence, one would expect to observe a distribution of heart failure versus no 
heart failure that was the same by strata of what was observed in the other data source. 
Specifically, if 165/1270, that is 13%, of patients are considered to have heart failure 
according to the medical record, this distribution would be 13% with heart failure among 
the 114 who self-reported heart failure (n=14.82) and 13% with heart failure among the 1156 
who did not (n=150.28). Thus, the expected number of cases in cell “a” would be 14.82 and 
the expected number of cases in cell “d” would be 1005.81, and the agreement would be 
100x(14.82+1005.81)/1270=80%. 
Given the low prevalence of heart failure, even in this sample of patients with chronic 
diseases, the probability of no heart failure is so high that the agreement expected by chance 
becomes very high. In other words, regardless of the other data source, in any data source 
the likelihood of no heart failure is so high that the probability of both data sources 
reporting no heart failure is also high. 
The kappa coefficient aims at quantifying concordance beyond that expected by chance 
alone, to avoid overestimation of true concordance when looking at absolute agreement. The 
underlying idea is that concordance varies from 0 to 100% (no cases concordant to all cases 
concordant). The absolute agreement is the proportion of concordant cases directly observed 
(in this case 86%). If it was true that the information registered in both data sources was 
independent of each other, by chance alone one would expect to have observed concordant 
classification in 80% of cases. So, 86% is only 6% higher than expected by chance under 
independence. Departing from the expected agreement due to chance, the maximum 
increase in agreement up to perfect concordance is 20% and kappa expresses the 6% increase 
as a proportion of this maximum possible: 6/20=0.3 (Fig. 1). 
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Fig. 1. Interpretation of kappa coefficient. 
Assuming the meaning and interpretation of the kappa coefficient is now clear, its definition 
is: k=(absolute agreement – expected agreement) / (100 – expected agreement). In our 
example, k=(86-80)/(100-80)=0.3. 
It is clear that kappa is zero when the absolute agreement is equal to that expected by chance 
and its maximal value is 1, when the absolute agreement is 100%, that is, perfect concordance. 
In theory it can take up negative values if the observed absolute agreement is lower than that 
expected by chance, but if this happens in situations where you expect some agreement, check 
for errors in coding of variables in your database before you accept the result.  
There are suggestions of ranges of values for kappa to be interpreted as excellent, good, fair 
or poor agreement but no universal solution exists. The same value might be considered 
excellent if we are assessing the concordance between scales to measure a subjective and 
imprecise phenomenon, while it may be unacceptably low when assessing for example the 
concordance between two laboratory methods to measure the same protein.  
Many software packages are available to calculate kappa coefficients, along with confidence 
intervals estimation, and for more complex scenarios than a two-rater or two-method 
classification of a dichotomous variable.  
Obviously, the kappa coefficient is adequate to assess the concordance in categorical 
variables that are expected to have the same value. It can be used to quantify the inter- or 
intra-observer reproducibility (between observers that rate the same subjects or repeated 
measurements by the same observer), an instrument’s precision, or, as in the case presented, 
the agreement between different methods of assessing the same construct. 
The agreement between two observers/methods in assessing a continuous variable cannot be 
approached with the calculation of a kappa coefficient, unless the results are categorized, 
resulting in loss of information. The correlation coefficient between two continuous variables, 
such as for example two measurements of the same phenomenon by different methods or 
different observers, measures the extent to which they are linearly related, and concordant 
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observations are obviously expected to be strongly correlated. However, very high correlations 
do not necessarily reflect agreement. An extreme example illustrates this clearly: the 
correlation between x and 2x is perfect, yet for no subject will they be equal except when x=0.  
Over 20 years ago, Bland and Altman proposed a graphical method to assess agreement 
between methods of clinical measurement (Bland & Altman, 1986). This method is based on 
the graphical display of the difference between the two raters/methods (Y axis) against the 
average of both values for each subject (X axis).  
Let us see how this applies with an example. A frequently raised question in clinical practice 
that has important implications on therapeutic decisions in the management of heart failure 
is that estimates of ejection fraction vary between alternative methods of assessing it, 
namely standard two-dimensional echocardiogram, nuclear imaging perfusion studies and 
magnetic resonance.  
Mistry et al. determined left ventricular ejection fraction and end-diastolic volumes in 150 
patients treated for acute ST-elevation myocardial infarction using four imaging studies – 
standard echocardiography (standard echo), contrast echocardiography (contrast echo), 
single-photon emission computed tomography (SPECT), and magnetic resonance imaging 
(MRI) (Mistry et al., 2010). Fig. 2 depicts a sample of Bland-Altman plots for left ventricular 
ejection fraction and end-diastolic volume from this study.  
 
Fig. 2. Agreement in estimation of left ventricular ejection fraction and end-diastolic volume 
between standard echocardiography (standard echo), contrast echocardiography (contrast 
echo), single-photon emission computed tomography (SPECT), and magnetic resonance 
imaging (MRI). Adapted from (Mistry et al., 2010) with kind permission of Elsevier. 
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With the graph and a few simple calculations, one can extract several informations. Firstly, 
is the mean difference close to zero? Under perfect concordance, not only would the mean of 
individual differences be zero but all differences (for all subjects) should be zero. Secondly, 
is the distribution of differences symmetrical in relation to the horizontal line at the mean of 
differences? Such symmetry argues in favor of random variation explaining the dispersion. 
The correlation coefficient between measurements' difference and their mean tests for the 
presence of systematic error (bias), with higher values suggesting more severe bias. Thirdly, 
what are the boundaries for variation in differences? These are usually presented and 
quantified using 95% limits of agreement which are no more than the limits of the interval 
between 1.96 times the standard deviation of the difference above and below the mean 
difference. Of course that this works well if the width of variation of differences does not 
differ much by the average value from the two methods.  
In some cases (Fig. 2, Panel C), the width of the variation in differences is larger for higher 
values of the variable and then it is best to use the logarithm of the initial variables which 
corresponds to assessing the relative instead of absolute differences. 
Bland–Altman analysis of ejection fraction measured by all four imaging modalities showed 
generally low mean differences but wide limits of agreement. Left ventricular end-diastolic 
volume was systematically larger when assessed by MRI and, when assessed by SPECT in 
comparison with contrast echo, it was higher by SPECT only for severely dilated cavities 
(Fig. 2). While it is known that MRI is the most valid method, it is relevant to assess 
concordance of alternative methods with the standard since MRI is not always feasible. 
The reproducibility of clinical findings in heart failure is important not only at the time of 
diagnosis but also to interpret changes or absence of change over time, namely because 
physical examination findings, specifically the jugular venous pressure coupled with 
biomarker trends, are useful in timing discharge planning or making therapeutic decisions. 
For example, in order to assess how large the variation between measurements of NT–pro-
BNP can be in patients with clinically stable heart failure, we measured its plasma 
concentration at rest repeatedly at 3-week intervals, in 118 patients. The results supported the 
clinical use of NT–pro-BNP in the monitoring of patients with HF with high NT–pro-BNP 
levels (>1,300 pg/mL). In these patients, variations between around 30% more and 30% less 
than the baseline can be expected without clinical improvement or deterioration; therefore, 
only changes larger than these should be valued. In patients with lower mean values, the 
variability was even larger, but in those patients the answer to the appropriateness of 
monitoring the biomarker over time is not as relevant (Araújo et al., 2006). 
Lack of concordance can result from lack of precision or systematic error. Its correct 
interpretation depends on judgment and familiarity with the question being studied. For 
example, in the study cited above where the relative completeness and validity of 
ambulatory medical record and patient’s self-report as data sources for evaluating the 
quality of care setting was assessed (Tisnado et al., 2006), when data on echocardiogram as a 
delivered service were analyzed, that is, whether the patient had undergone an 
echocardiograhic examination, the concordance between medical record and patient’s self-
report was very low (absolute agreement 55%, kappa=0.1). This could have happened for 
several reasons, some representing systematic error in medical records, such as the absence 
of registration of ordered tests, the fact that an ordered test might not have been done, etc, 
systematic error in patient’s self-report, such as the patient not knowing that the test 
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performed was an echocardiogram, etc, or by lack of precision of both data sources. The 
point is that concordance is not a good measure of validity, even if one of the 
methods/observers can be considered the standard against which the other(s) is(are) being 
assessed. Measurement of validity particularly applied to diagnosis will be addressed in the 
next section of this chapter. 
2.2 Validity 
Validity of a piece of information for diagnosis, be it a fact collected by clinical history, a 
finding (or lack thereof) in physical examination or the result of an ancillary test, is assessed 
by confronting that information with the true state regarding presence or absence of a 
certain disease one is aiming to confirm or rule out. 
The first challenge is that very often there is no good standard to define the true state. 
Sometimes, only the test of time or response to therapy can bring a definite conclusion 
regarding a hypothetical diagnosis, but these are affected by other factors, such as 
competitive risks, effectiveness of interventions, determinants of the treatment decisions and 
assessment of the patient’s condition after some follow up time. Also, even if there is a 
standard with which to compare a test whose validity one aims to assess, if the standard is 
not perfect, and it seldom if ever is, apparent lack of sensitivity of the new test may result 
from mere lack of specificity of the standard (false positive cases in assessment with the 
standard are actually well classified as negative by the new test, but since the standard is 
our reference, we see the test result as false negative) and apparent lack of specificity of the 
test may result from lack of sensitivity of the standard. 
In comparing with the standard, the accuracy of the test results is usually quantified with 
two measures of the proportion of correctly classified cases: sensitivity is the proportion of 
true cases that are considered positive by the test and specificity is the proportion of true 
non-cases that are considered negative by the test. 
Specificity, like sensitivity, is often considered an intrinsic property of a test and therefore 
independent of the population under study. However, as specificity is determined by 
unaffected individuals who have positive results, it is in fact dependent on the characteristics 
(even subclinical) of this comparison population (Rutjes et al., 2005). It is critical to evaluate the 
study design from which the specificity of a test has been determined and to consider whether 
the test can be used more appropriately to distinguish one disease from another or to 
distinguish the presence or absence of disease. Also, sensitivity is vulnerable to variation 
depending on the spectrum of severity of the cases studied (Lunet et al., 2009; Ransohoff & 
Feinstein, 1978). For example, due to these spectrum effects and characteristics of the 
comparison population, published values for sensitivity and specificity of a long list of history, 
physical examination and ancillary tests for the diagnosis of heart failure as the cause of 
dyspnea in the emergency department (Wang et al., 2005) do not necessarily apply to the same 
clinical findings in primary care or in an epidemiologic study in the general population. 
All clinicians understand that predictive value is critical for moving beyond the simplicity of 
sensitivity and specificity for interpretation of test results. In simple terms, the starting point 
of a clinical encounter immediately influences the probability of the patient being affected 
by a certain disease one may be trying to diagnose. Whether the patient came by his 
initiative due to a complaint or referred by another colleague or was actually called for a 
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screening procedure, the clinician, more or less consciously depending on personal 
characteristics and the circumstances, immediately elaborates a list of possible diagnoses, 
ordered by the probability of being the right diagnosis for that case. He then works from 
there to gather additional information that will help reorder this list, hopefully bringing 
some hypotheses to become such remote possibilities that they are excluded and a few, 
preferably one, to such high probability that it is considered the final diagnosis. 
In everyday clinical practice with individual patients, quantitative probability theory is usually 
not explicitly used. However, diagnostic reasoning, as described in the previous paragraph, 
involves a probabilistic approach and takes into account the validity of tests when 
incorporating their results in the process of diagnosis. To interpret any diagnostic test, one 
must have information not only about the test’s characteristics but also about the patient (or a 
population with similar characteristics). Incomplete epidemiological information that 
facilitates estimation of pretest probability certainly contributes to the challenge (Bianchi & 
Alexander, 2006). Few tests are inherently accurate enough to “rule in” or “rule out” disease 
effectively in all cases. We should look at results as altering disease probability. This requires 
estimation of a pretest probability that will be adjusted up or down by the test results (Bianchi 
& Alexander, 2006). This is bayesian logic, which uses an adjustment factor called the likelihood 
ratio to convert a pretest probability into a posttest probability (Grimes & Schulz, 2005). 
 
Fig. 3. Change from pre- to posttest probability, after a BNP test result is obtained, 
considering a positive (≥100pg/mL, red line) or negative (<100pg/mL, blue line) test result, 
with likelihood ratios of approximately 4 and 0.1, respectively (Wang, 2005), in three 
hypothetical scenarios in the emergency department: A – acute lung edema (pretest 
probability assumed to be 95%); B – unspecific malaise in an old patient without previous 
diagnosis of heart disease (pretest probability assumed to be 10%); C – aggravated dyspnea 
in a heavy smoker, with chronic obstructive lung disease and past history of myocardial 
infarction (pretest probability assumed to be 50%). 
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The key feature of the likelihood ratio is that, unlike traditional indices of validity, it 
incorporates all four cells of a 2-by-2 table (Grimes & Schulz, 2005). Likelihood ratios help 
clinicians to navigate zones of clinical uncertainty. Building on an accurate pretest 
probability of disease, likelihood ratios from ancillary tests can refine clinical judgment.  
Clinicians should be wary of ordering tests when the pretest probability of disease is high or 
low. Tests are unlikely to alter disease probability and will only confuse the situation: 
unexpected results will usually be false-positives or false-negatives. Consider for example 
the scenarios represented in Fig. 3. In the case of an acute lung edema (Panel A), in which 
the clinical diagnosis is generally very accurate, a high BNP level will increase our certainty 
of the diagnosis from 95% to almost 99%, which is irrelevant. A low BNP value, on the other 
hand, does not exclude the diagnosis of heart failure and would still leave us thinking that 
the diagnosis is more likely (66%) to be heart failure than not. The correct clinical attitude 
would be to treat the acute lung edema immediately, avoiding the delay and cost of the test. 
If, on the contrary, the pretest probability is low (Panel B), then a low BNP value would only 
tell us what we already know and a high BNP would more likely be a false positive than 
represent heart failure. It is in the case of uncertainty (Panel C depicts equal probability of 
the diagnosis being heart failure or not, the maximum uncertainty) that the test is more able 
to change our thought: a high BNP value will yield a predictive value of 80%, which in the 
emergency department and for the hypothesis of heart failure is enough to decide treating 
as such, while a low BNP will practically exclude heart failure or at least lower its 
probability so much as to guide the diagnostic work-up in alternative directions. 
Likelihood ratios enable clinicians to interpret and use the full range of diagnostic test 
results, not only dichotomous. For each test result, the likelihood ratio is the ratio between 
the probability of that result among cases to the probability of that same result among non-
cases. Thus, test results with likelihood ratio close to 1, say between 0.5 and 2, are not 
informative because they are practically as likely to occur in cases as in non-cases and do not 
change the probability in the diagnostic reasoning. High likelihood ratios above 1 increase 
the probability of disease and low likelihood ratios below 1 decrease it. Going one step 
further from dichotomous test results, likelihood ratios can help deal with grey zones. For 
example, natriuretic peptides have a very low likelihood ratio for low plasma values, say 
<30 pg/mL, in untreated patients and reasonably high likelihood ratio for high values, say 
>250 pg/mL (Bettencourt, 2005; Wang, 2005). Between these two cut points, it is not such an 
informative test. 
Ruling disease in or out (or considering subsequent decisions on management) depends on 
a comparison of posttest probability with thresholds for further action based on factors such 
as severity of disease, risks of further testing, or side effects of treatment. The posttest 
probability is the predictive value. Test results cannot be said to have predictive value; only 
a test result in a given patient (or population) has predictive value (Bianchi & Alexander, 
2006). 
Recognizing that most tests are imperfect and therefore do nothing more than adjust 
probability, which may or may not “rule in” or “rule out” the disease depending on the 
situation, protects against the misconception that a result can be interpreted without 
considering pretest probability.  
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The medical history and physical examination remain fundamentally important. Indeed, a 
precise assessment of the chance of disease can be far more important than the likelihood 
ratios of sophisticated, usually expensive and sometimes dangerous tests. Although clinical 
diagnosis might not necessarily be more accurate than ancillary testing, its accuracy has a 
striking effect on the interpretation of any test results that follow. An accurate pretest 
probability and subsequent testing can greatly improve clinical diagnosis.  
Tests can build on each other in sequence as long as they are independent. Test 
independence means that the result from one test cannot bias the outcome of the next, such 
that the posttest probability after one test becomes the pretest probability of the subsequent 
test. 
The purpose of diagnostic work-up is to assess whether the probability of disease is above 
or below the treatment threshold. Tests should only be used when they will affect 
management. If a clinician’s pretest probability of disease securely rules in or out a 
diagnosis, further testing is unwarranted. More testing should be considered only in the 
murky middle zone of clinical uncertainty. The location of the decision thresholds along the 
continuum of diagnostic certainty needs to be determined before testing is done and should 
be tailored to the specific patient. Using a nomogram or a simple calculation, a clinician can 
estimate how high or low a likelihood ratio would have to be to shift the pretest probability 
down to exclude the diagnosis or up to begin treatment. If no test result would achieve this 
shift in probability, the test should not be done (Grimes & Schulz, 2005). 
2.3 Early diagnosis (and screening?) 
The increasingly deeper understanding of the pathophysiology of heart failure led to the 
definition of stages of heart failure (Hunt et al., 2001), considering asymptomatic cardiac 
dysfunction as an intermediate step to the development of overt heart failure. Long before 
this paradigm was established, the importance of asymptomatic left ventricular systolic 
dysfunction, one of the most important cardiac abnormalities underlying heart failure, was 
recognized. This recognition is related not only to its frequency, with a prevalence at least as 
high as that of symptomatic heart failure, but also to the fact that inhibition of the renin-
angiotensin-aldosterone system could delay or prevent progression to symptomatic heart 
failure.  
However, screening asymptomatic patients for heart failure remains controversial. In the 
Cardiovascular Health Study, only 9% of elderly patients who ultimately developed systolic 
heart failure had a reduced left ventricular ejection fraction on study enrollment, on average 
5.5 years before (Gottdiener et al., 2000).  
Biomarkers, such as the already mentioned natriuretic peptides, could potentially play this 
role; however, the cost-effectiveness and target populations for these strategies remain 
unsettled (Betti et al., 2009). For example, in the Olmsted County cohort, with a low 
prevalence of left ventricular systolic dysfunction (1.1%), 24% of the population would 
require an echocardiogram based on raised BNP concentrations and the vast majority of 
these echocardiograms (96%) would reveal an ejection fraction over 40%. The performance 
of BNP and NT-proBNP for the detection of left ventricular systolic dysfunction in the 
community is fair, mainly because of the low specificity, compromising the potential 
usefulness of the test as a screening procedure. Therefore, BNP testing for screening for left 
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ventricular systolic dysfunction in the general population is not recommended (Bettencourt, 
2005). 
Effective primary and secondary prevention to decrease the burden of heart failure can be 
expected to be attained through adherence to existing guidelines and reduction of the 
financial and psychosocial barriers that impair adherence to prescribed medical therapy and 
lifestyle changes recommendations. In clinical practice, it is the practitioner’s responsibility 
to search with clinical examination alone for latent structural heart disease and manifest 
heart failure, in a case-finding more than screening approach (Raffle & Muir Gray, 2007). 
Such screening can be accomplished by asking a simple series of questions related to the 
occurrence of such symptoms as easy fatigability, functional limitations, and development 
of lower extremity swelling (Ramani et al., 2010). This approach would contribute to better 
refine the pretest probability of ancillary tests which would no longer be done for screening 
but rather for diagnosis.  
In general, the goodness of attempting an early diagnosis does not depend only on the 
existence of a valid test for identification of the altered state one is interested in identifying, 
but also on the ability to define an appropriate target population, that is, with a pretest 
probability upon which the test results can turn out to have acceptable predictive value. 
Moreover, early diagnosis should be considered only if effective treatment can be offered 
and the natural course of the disease changed by this intervention. Such effects on outcomes 
are best assessed using experimental approaches for complex interventions, that is, the 
intervention being tested should be the fact that early diagnosis is attempted and all 
consequences thereof. Obviously, such studies warrant a considerable investment of 
resources, adequate sample size and a favorable prior odds of successful long-term negative 
and positive predictive values. An interesting challenge is to create conditions in which 
these effects can be understood using observational or quasi-experimental research, namely 
using real-world data of actual practices and their relation with outcomes. 
2.4 Utility of a diagnostic test  
The rationale as to when a test should be applied requires a judgment that among patients 
to whom the test is administered, the costs of the illness, both monetary and physical, along 
with the cost of the test and the errors that arise when it does not classify patients 
accurately, will be exceeded by the costs of the illness, had the test not been done (Weiss, 
2006). 
The utility of a diagnostic test is multidimensional and its comprehensive assessment should 
take into account reproducibility, validity, feasibility, acceptability by subjects, costs and 
effects on decisions and clinical outcomes. This means that the answer may vary from place 
to place, institution to institution, physician to physician, and patient to patient. 
Earlier sections of this chapter have reviewed issues of reproducibility and validity. We will 
now briefly address the effect of diagnostic tests on decisions and clinical outcomes, 
illustrating with an example. 
The etiology of systolic heart failure affects prognosis and treatment. In newly diagnosed 
cardiomyopathy, the exclusion of underlying coronary artery disease and myocardium that 
might benefit from revascularization is critical. Patients with coronary artery disease  
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and concomitant heart failure have a worse prognosis than those with nonischemic 
cardiomyopathy, but myocardial function may substantially improve after 
revascularization, highlighting the importance of making the appropriate diagnosis early 
and accurately.  
Current European guidelines for the diagnostic work-up of acute and chronic heart failure 
recommend that coronary angiography should be considered in heart failure patients with a 
history of exertional angina or suspected ischemic left ventricular systolic dysfunction, 
following cardiac arrest, and in those with a strong risk factor profile for coronary heart 
disease, and may be urgently required in selected patients with severe heart failure (shock 
or acute pulmonary oedema) and in patients not responding adequately to treatment 
(Dickstein et al., 2008). 
Angiographic evidence of atherosclerosis does not necessarily mean that revascularization 
will be beneficial. Left ventricular dysfunction in patients with coronary artery disease can 
improve substantially and even normalize after coronary artery bypass grafting (CABG) 
surgery, presumably due to recovery of function by hibernating myocardium, which is 
defined as myocardial tissue with abnormal function but maintained cellular function. The 
assessment of myocardial viability with the use of single-photon-emission computed 
tomography (SPECT) or low-dose dobutamine echocardiography is commonly performed to 
predict improvement in left ventricular function after CABG, and numerous studies have 
suggested that the identification of viable myocardium also predicts improved survival after 
CABG (Allman et al., 2002). However, studies that suggested an association between 
myocardial viability and outcome were retrospective in nature, and it is uncertain in most of 
these studies whether the decision to perform CABG may have been driven by the results of 
the tests, whether adjustment for key baseline variables was adequate, and whether patients 
who did not undergo CABG received aggressive medical therapy for heart failure. 
Therefore, the efficacy of this approach is uncertain. 
The Surgical Treatment for Ischemic Heart Failure (STICH) trial was designed to compare 
the efficacy of medical therapy alone with that of medical therapy plus CABG in patients 
with angiographic documentation of coronary artery disease amenable to surgical 
revascularization and with left ventricular systolic dysfunction (ejection fraction ≤35%) 
(Velazquez et al., 2011). In the initial design of the trial, viability testing with SPECT was 
required for the enrollment of patients. However, due to unfeasibility of this requirement, 
the protocol was subsequently revised to make viability testing optional and to allow the 
use of either SPECT or dobutamine echocardiography for viability testing. Investigators at 
all study centers were strongly encouraged to perform viability testing in every patient, but 
the decision to perform the test was left up to the recruiting investigators. This resulted in 
only around half of patients in the trial undergoing viability testing. The differences in 
baseline characteristics between patients who underwent viability testing and those who did 
not undergo such testing suggest that at least some patients may have been selected for 
testing on the basis of clinical factors.  
The risk of death was strongly and significantly lower in patients with than without 
viability (hazard ratio, 0.64; 95% confidence interval, 0.48–0.86), but after adjustment for 
other prognostic baseline variables the between-group difference was no longer significant 
(Bonow et al., 2011).  
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In patients without viability, the hazard ratio of all-cause death for CABG versus medical 
therapy alone was 0.70 (95% confidence interval: 0.41-1.18) and in patients with viability 0.86 
(95% confidence interval: 0.64-1.16), p for interaction=0.53, which was interpreted as 
evidence that the effect of CABG does not depend on the existence of viability (Bonow et al., 
2011). Since in the STICH trial there was overall no significant difference between medical 
therapy alone and medical therapy plus CABG with respect to this primary end point 
(Velazquez et al., 2011), this may not be the best endpoint to assess an interaction with 
viability. Patients assigned to CABG, as compared with those assigned to medical therapy 
alone, had lower rates of death from cardiovascular causes and of death from any cause or 
hospitalization for cardiovascular causes (Velazquez et al., 2011); the authors did not find a 
significant interaction between myocardial-viability status and medical versus surgical 
treatment with respect to the rates of death from any cause or from cardiovascular causes or 
the rate of death or hospitalization for cardiovascular causes either (Bonow et al., 2011). 
Despite the strengths of the study described in comparison with the previous literature, the 
shortcomings acknowledged by the authors in the STICH trial leave some doubt regarding 
the effect of viability studies on clinical outcomes. The direct response to this question 
would warrant the randomization of patients to undergo viability testing or not. A 
pragmatic approach to estimate effectiveness would leave to the physicians’ discretion the 
decision of management after knowing the result (or not). 
Cost-effectiveness analyses are out of scope of this chapter. 
3. (Evidence-based) Management 
The fact that the decision to order a viability test, and then acting upon the observed result, 
is dependent on clinical characteristics and on the clinicians’ impression of the benefit a 
particular patient may derive from that approach introduces confounding when comparing 
outcomes of patients managed this way with those of patients managed otherwise. This is 
called confounding by indication (the indication for the intervention being tested, or the 
clinical “hunch” that such indication exists). 
Confounding by indication is one of the main reasons why a randomized controlled trial is 
the study design that creates best conditions for valid causal inferences in attributing an 
effect in outcomes to an intervention being tested, pharmacological or of other nature. The 
high position of randomized clinical trials in the hierarchy of study designs for intended 
effects of therapy derives from this requisite.  
Jan Vandenbroucke argues that we may have been deluding ourselves about their unique 
superiority because they start with much higher prior odds than most observational 
research (Vandenbroucke, 2008). In fact, for obvious reasons, clinical trials are conducted 
only under conditions of high probability of success (benefit of the intervention), specifically 
1:1, that is, “equipoise” (Djulbegovic et al., 2000) in the sense that it is at least as likely to be 
beneficial as not, which contributes to the much lower risk of not standing the test of time 
than observational research which is conducted under much lower prior odds 
(Vandenbroucke, 2008). 
This is not to suggest that this hierarchy is senseless or useless. This author suggests that we 
need two different hierarchies, the hierarchy of discovery and explanation and that of 
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evaluation, to assess the evidence of studies designed and conducted for different purposes. 
Etiologic researchers should pursue low probability hypotheses because these may lead to 
new insights, particularly if they are able to take advantage of detecting what was wrong 
when they go down the wrong way (Vandenbroucke, 2008).  
In conclusion, the widely accepted hierarchy of levels of evidence in clinical research must 
be interpreted specifically for the context of evaluation of interventions, be them 
pharmacological or as “macro” as the organization of services. 
It is not the purpose of this text to review extensively the principles and characteristics of 
clinical trials and several sources of literature can be found regarding this issue. I suggest 
introductory epidemiology books for a more rapid overview of the fundamental concepts 
and principles in study design, Haynes et al’s Clinical Epidemiology for a thorough review 
from the clinical point of view with sensible calls of attention useful for interpretation 
(Haynes et al., 2006), and Friedman and DeMets’ references for more applied approach 
based on case studies covering also execution issues (DeMets et al., 2006; Friedman et al., 
2010). 
In aiming to provide the concepts and develop competencies necessary for using the 
medical literature and making clinical decisions, as announced at the beginning of this 
chapter, we will briefly review an issue that is often misunderstood by clinicians, leading to 
misinterpretation of the results of trials, and which is intimately related with issues of 
precision and validity discussed in previous sections. 
When, as is the case for most outcomes in heart failure, there are several interventions with 
well documented benefit and clearly recommended, alternative options for the same effect 
are tested under non-inferiority and equivalence hypotheses, raising the need to define 
minimally important differences, which must be established based on knowledge of the 
natural history of disease guided by clinical judgment. One major condition for credibility of 
trials is complete preplanning of every aspect of the trial and advance registration and 
documentation of everything that was preplanned (Laine et al., 2007), including the a priori 
definition of this threshold of effect (Moher et al., 2010).  
If a study is designed to test whether a new treatment is significantly different from the 
control intervention at the 5% significance level, with the null hypothesis being no 
difference between groups (relative risk = 1 or difference = 0), the absence of a significant 
difference, that is, failure to reject the null hypothesis, is not synonymous with the 
interventions being clinically equivalent. Absence of proof of difference is not proof of 
absence of difference (Haynes et al., 2006). Minimally important differences from the clinical 
point of view must be defined beforehand and then the results must be interpreted in light 
of these thresholds and considering the whole width of the confidence interval of the effect 
estimate (Haynes et al., 2006). 
Let us consider an example. In chronic heart failure, inhibition of the renin–angiotensin–
aldosterone system by angiotensin-converting enzyme inhibitors improves survival and 
decreases morbidity, improving exercise capacity, quality of life, and left ventricular 
function and size (Konstam et al., 1993; Konstam et al., 1992). Although a cornerstone in the 
treatment of heart failure, angiotensin-converting enzyme inhibitors are underused, partly 
due to side effects. If proven at least similarly efficacious to angiotensin-converting enzyme 
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inhibitors, angiotensin-receptor blockers could at least be considered an alternative due to 
their superior tolerability. The primary objective of the HEAVAN study was to test the 
hypothesis that valsartan, in comparison with enalapril, is at least as effective on exercise 
capacity, measured as distance walked during a 6-minute walk test, in heart failure patients 
stabilised on an angiotensin-converting enzyme inhibitor (Willenheimer et al., 2002). 
 
Fig. 4. Schematic representation and interpretation of 4 possible results of the HEAVAN 
study. The horizontal two-headed arrows represent the 95% confidence interval of the 
difference between the valsartan and enalapril treatment groups in the change, from 
baseline to after treatment, in distance walked in 6 minutes. 
Non-inferiority was defined as a treatment effect of valsartan, with respect to mean change 
from baseline in the distance walked during the 6-minute walk test, better than 45 m less 
than that of enalapril.  
A distance of 45 m was chosen based on an expected average baseline 6-min-walk test 
distance of 450 m, since a difference of 10% in this distance is not considered clinically 
relevant (Willenheimer et al., 2002). The 10% threshold must at least cover the imprecision of 
the outcome measurement, if not more, as long as there is fundament from previous data. 
For example, if one was to study the effect of some intervention on the change in NT-
proBNP in chronic heart failure patients, only variations beyond 30% of baseline, upwards 
or downwards, should be considered clinically important, given the (apparently random) 
fluctuation of this biomarker under clinical stability, as described above (Araújo et al., 2006). 
In the HEAVAN study, the null hypothesis under test is not that there is no difference 
between treatments. Rather, this is an example of a situation where a one-sided test best 
suits the underlying reasoning. Unilateral questions warrant one-sided answers (Haynes et 
al., 2006). The four hypothetic scenarios represented in Fig. 4 show a situation of equivalence 
(I), with the limits of the confidence interval of the difference between treatments not 
surpassing 45 m in either direction; non-inferiority (II), with the lower limit of the 
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confidence interval excluding the possibility of enalapril being more than 45 m more 
beneficial than valsartan, that is, the data are compatible with valsartan being better than or 
equivalent to enalapril, but not inferior; scenario III is the most vulnerable to 
misinterpretation, since the fact that zero difference is not excluded from the range of the 
confidence interval does not mean that the two interventions are not different and in fact in 
the situation represented in the figure, the superiority of enalapril, beyond 45 m, cannot be 
excluded based on the data; superiority (IV) implies that the whole confidence interval is 
beyond the minimal clinically important difference of 45 m. 
Reaching target doses of angiotensin-converting enzyme inhibitors was once the main 
(process) objective when treating systolic heart failure patients. Angiotensin receptor 
blockers were initially candidates to replace angiotensin-converting enzyme inhibitors in 
case of low tolerability, as described above, but there is now evidence that adding an 
angiotensin receptor blocker to angiotensin-converting enzyme inhibitor leads to a further 
clinically important reduction in relevant cardiovascular events in such patients (McMurray 
et al., 2003), possibly even when a beta-blocker and an aldosterone antagonist are 
concurrently prescribed (Weir et al., 2008). The current state-of-the-art management of heart 
failure involves use of multiple drugs, which are not free from side-effects particularly when 
used together and in high doses, with a lower benefit being generally obtained if the highest 
tolerated dose up to the target is not used. Moreover, patients in need of such care are old 
and with multiple comorbidities, but it is important to emphasize that the recommended 
schemes can be tolerated with benefit by a large proportion of patients under the care of 
experienced professionals. 
The complexity of the heart failure syndrome, together with the increasingly recognized 
need for demonstration of cost-effectiveness of interventions, motivates research to assess 
the effect of specialized multidisciplinary heart failure management programmes. The 
heterogeneity of the content and organization of these programmes in large part justifies 
conflicting results (McDonagh et al., 2011). On the other hand, observational approaches to 
study the effect of such interventions have been threatened by serious selection bias and 
confounding by indication (Azevedo et al., 2002). However, experimental evidence has been 
accumulating supporting the benefit of a range of models of programmes and it is generally 
accepted that specialized teams of different kinds are more successful in achieving higher 
rates of patients under recommended prognosis modifying drug and device therapy, with 
drug doses closer to the recommended targets and overall benefit for patients namely in 
reducing hospitalizations. Consequently, heart failure management programmes are 
recommended for patients with HF recently hospitalized and for other high-risk patients 
(Dickstein et al., 2008). 
4. Prognosis 
Physicians need to counsel patients about prognosis to enable informed decisions about 
medications, devices, transplantation, and end-of-life care. 
Heart failure has an ominous prognosis, particularly after an acute heart failure episode 
requiring hospitalization. Half of patients admitted with acute heart failure are readmitted 
within 6 months (Bettencourt et al., 2004; Jong et al., 2002). Analysis of 100 000 cases of acute 
decompensated heart failure in the United States revealed that in-hospital mortality after 
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hospital admission ranges from 5% to 8%, with 1-year mortality averaging 40% to 60% 
(Adams Jr et al., 2005). It has been general practice to discharge patients according to 
improvement in symptoms, but, given the reproducibility and validity of clinical 
examination discussed above, it becomes clear that this decision threshold suffers from 
severe inter-observer variability. Some studies have tried to identify patients at higher risk 
of death and/or readmission who might benefit from more intensive therapy. Also for this 
prognosis issue, natriuretic peptides were good candidates for objective assessment of risk 
since they decrease in close correlation with falling wedge pressures, and correlate with 
functional capacity.  
We followed a sample of 156 patients consecutively admitted to the hospital due to acute 
decompensated heart failure and discharged alive, excluding acute coronary syndromes, for 
the primary end-point of death or hospital readmission for 6 months. The plasma 
concentration of NT-proBNP at admission was not associated with the endpoint, in contrast 
with that at discharge, suggesting that it is the change in response to therapy during 
hospitalization, that matters most. Thus, to refine the risk stratification with the dynamic 
perspective of change in neuro-humoral activation, we studied the effect of the relative 
change in NT-proBNP from baseline to discharge. Categories of this new variable were 
defined according to a change of at least 30%, in agreement with the clinical meaning that 
can be attributed to the time variation discussed above. The results are depicted in Fig. 5 
and clearly show an increase in risk that can be predicted from the change in NT-proBNP 
during hospitalization and which was independent of clinical signs of volume overload at 
discharge, thus confirming that new information is being obtained from this biomarker 
(Bettencourt et al., 2004). 
 
Fig. 5. Cumulative hospitalization-free survival according to patterns of response of NT-
proBNP (decreased by ≥30% of baseline value, changed by <30%, increased by ≥30%). 
Reprinted from (Bettencourt et al., 2004) with kind permission of Wolters Kluwer Health. 
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Many clinical, laboratory and functional variables have been identified as associated with 
prognosis in chronic and acute heart failure patients. Clinical prediction rules include 
simultaneous consideration of several factors in predicting the prognosis of individual 
patients. 
Evaluation of prediction models should consider two attributes. Discrimination is related to 
higher values of the predicted value of the outcome being obtained among those who 
actually develop the outcome. This is exactly what the area under a ROC curve represents, 
specifically the probability that a random person with the outcome has a higher value of the 
measurement than a random person without the outcome (Altman & Bland, 1994). 
Calibration goes a step forward and measures to which extent the model predicts well what 
will happen. This is usually done with a goodness-of-fit test such as the Hosmer-Lemeshow 
statistic (Lemeshow & Hosmer, 1982) or by simply comparing predicted and observed 
numbers of events, usually by deciles of predicted risk. Deviations in absolute risk 
prediction are important when applying a model for clinical decision-making and suggest 
that recalibration might be necessary, which consists in correcting the baseline risk function 
with data from the population in which the model is to be used while importing the 
coefficients (if discrimination is good). 
Most existing models to predict the risk of death or urgent transplantation in heart failure 
have features that may limit their applicability. These models relied on either peak oxygen 
consumption or invasive measures of cardiac performance, and most have not been 
validated in another sample than the one used for its development. An exception is the 
Seattle Heart Failure Model (SHFM) which allows prediction of survival of heart failure 
patients with the use of easily obtained clinical characteristics. The model provides an 
accurate estimate of mean, 1-, 2-, and 3-year survival and is unique in allowing estimation of 
effects of adding medications or devices to a patient’s regimen (Levy et al., 2006), potentially 
contributing to the better prediction of mortality than clinical characteristics alone, because 
medications and devices are critically altered by physicians to improve the chances of 
survival of their patients. The model was developed using previously collected data in a 
cohort of 1125 patients with predominantly left ventricular systolic heart failure [the 
Prospective Randomized Amlodipine Survival Evaluation (PRAISE)] and 9942 patients from 
other 5 cohorts were used to prospectively validate the model. PRAISE was a randomized 
trial of amlodipine versus placebo among patients in the United States and Canada with 
ejection fraction below 30% and New York Heart Association functional class IIIB to IV heart 
failure (Packer, 1996, as cited in (Levy et al., 2006)). 
The SHFM and 3 other predictive models, namely Acute Decompensated Heart Failure 
National Registry (ADHERE), the American Heart Association Get With The Guidelines-
Heart Failure score (GWTG-HF), and Association of Health Aging and Body Composition 
Heart Failure score (ABC), were all calculated in each of 2472 consecutive patients 
hospitalized with acute heart failure. The authors compared predicted and observed 
mortality and also compared the predicted mortality with the observed composite end 
point, including death, heart transplantation, or implantation of left ventricular assist device 
(Nakayama et al., 2011). For all the outcomes assessed, the SHFM had highest 
discrimination as indicated by a higher area under the receiver operating characteristic 
curve (Fig. 6). 
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Fig. 6. Area under the receiver operating characteristic curves (AUC) for combined end 
point of death, heart transplantation, or left ventricular assist device implantation for Seattle 
Heart Failure Model (SHFM), Acute Decompensated Heart Failure National Registry 
(ADHERE), the American Heart Association Get With The Guidelines-Heart Failure score 
(GWTG-HF), and Association of Health Aging and Body Composition Heart Failure score 
(ABC), for (A) in-hospital death, and combined end points at (B) 30 days and (C) 1- and (D) 2 
years of follow-up. Reprinted from (Nakayama et al., 2011) with kind permission of Elsevier. 
Calibration analysis, presented in Fig. 7, shows absence of important or significant differences 
between predicted and observed events, supporting the validity of this prognostic model for 
populations quite different from those of the original study, and indicating that the SHFM is 
also an adequate risk prediction model in patients with milder heart failure.  
Much of the accumulated evidence on the prognosis of heart failure resulted from the 
prospective assessment of outcomes in patients included in the negative control arm of 
randomized clinical trials in which a patient population might have been limited because of 
strict enrollment criteria, resulting in the exclusion of patients with severe conditions and 
comorbidities. With the development and generalization of access to informatic resources, 
large administrative databases and electronic medical records have increasingly been used 
to fit risk prediction models to assess prognosis. Major issues raised by these settings and 
www.intechopen.com
 
Epidemiology – Current Perspectives on Research and Practice 
 
190 
data sources are the generalizability of results from randomized trials and completeness and 
accuracy of data from large administrative databases or electronic medical records.  
 
Fig. 7. (A) Comparison of predicted and observed survival for the Seattle Heart Failure 
Model (SHFM). Predicted (blue) versus observed (white) survival rate at each day plotted 
during follow-up period of ≤3 years. Calibration plots for composite outcome at (B) 30 days 
and (C) 1 and (D) 2 years for SHFM. Hosmer-Lemeshow chi-square was 7.21 (p = 0.51), 11.15 
(p = 0.19), and 5.04 (p = 0.74) at 30 days and 1 and 2 years, respectively. Reprinted from 
(Nakayama et al., 2011) with kind permission of Elsevier. 
Technological evolution led to the possibility of telemonitoring patients and continuously 
collecting physiological data through implanted devices. These large amounts of data, 
representing repeated measures over time, raise new challenges for the inclusion of all those 
time-varying data as independent variables in risk prediction models. 
5. Conclusion 
In contrast to other major cardiovascular diseases in developed countries, heart failure is a 
growing problem as the population ages and survivors of myocardial infarction live longer. 
The successful management of this population depends on risk factor reduction via lifestyle 
www.intechopen.com
 
Clinical Epidemiology: Principles Revisited in an Approach to Study Heart Failure 
 
191 
modification and application of currently established guidelines. During the past 3 decades, 
a combination of pharmacological, device-based and surgical treatment modalities has 
tremendously enhanced the survival and quality of life of patients with heart failure. 
Technological developments improve our capacities but also raise new challenges for their 
proper use. 
The concepts and tools reviewed in this chapter help clinicians and researchers deal with 
uncertainty. Continued application of these principles in clinical practice and research is 
vital for optimal medical care for heart failure patients. These are, however, general 
principles that apply to clinical practice in other areas and heart failure was merely an 
example setting. 
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